Logo image of PULM

PULMATRIX INC (PULM) Stock Fundamental Analysis

NASDAQ:PULM - US74584P3010 - Common Stock

4.93 USD
-0.03 (-0.6%)
Last: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, PULM scores 3 out of 10 in our fundamental rating. PULM was compared to 193 industry peers in the Pharmaceuticals industry. PULM has a great financial health rating, but its profitability evaluates not so good. PULM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PULM had negative earnings in the past year.
PULM had a negative operating cash flow in the past year.
PULM had negative earnings in each of the past 5 years.
PULM had a negative operating cash flow in each of the past 5 years.
PULM Yearly Net Income VS EBIT VS OCF VS FCFPULM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

PULM's Return On Assets of -128.90% is on the low side compared to the rest of the industry. PULM is outperformed by 80.31% of its industry peers.
PULM's Return On Equity of -141.51% is on the low side compared to the rest of the industry. PULM is outperformed by 63.73% of its industry peers.
Industry RankSector Rank
ROA -128.9%
ROE -141.51%
ROIC N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
PULM Yearly ROA, ROE, ROICPULM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PULM Yearly Profit, Operating, Gross MarginsPULM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
PULM has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, PULM has more shares outstanding
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PULM Yearly Shares OutstandingPULM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PULM Yearly Total Debt VS Total AssetsPULM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -51.71, we must say that PULM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -51.71, PULM is not doing good in the industry: 90.67% of the companies in the same industry are doing better.
PULM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -51.71
ROIC/WACCN/A
WACC9.96%
PULM Yearly LT Debt VS Equity VS FCFPULM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

PULM has a Current Ratio of 11.21. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a Current ratio of 11.21. This is amongst the best in the industry. PULM outperforms 84.97% of its industry peers.
A Quick Ratio of 11.21 indicates that PULM has no problem at all paying its short term obligations.
PULM has a Quick ratio of 11.21. This is amongst the best in the industry. PULM outperforms 84.97% of its industry peers.
Industry RankSector Rank
Current Ratio 11.21
Quick Ratio 11.21
PULM Yearly Current Assets VS Current LiabilitesPULM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.78% over the past year.
PULM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.76%.
The Revenue has been decreasing by -0.26% on average over the past years.
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.35%
Revenue 1Y (TTM)-96.76%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%

3.2 Future

PULM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.43% yearly.
Based on estimates for the next years, PULM will show a very strong growth in Revenue. The Revenue will grow by 43.66% on average per year.
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PULM Yearly Revenue VS EstimatesPULM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PULM Yearly EPS VS EstimatesPULM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PULM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PULM Price Earnings VS Forward Price EarningsPULM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PULM Per share dataPULM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PULM's earnings are expected to grow with 28.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.57%
EPS Next 3Y28.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PULM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMATRIX INC

NASDAQ:PULM (8/29/2025, 8:00:01 PM)

4.93

-0.03 (-0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners8.85%
Inst Owner Change5.75%
Ins Owners0.66%
Ins Owner Change0%
Market Cap17.99M
Analysts82.86
Price TargetN/A
Short Float %0.47%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48.77
P/FCF N/A
P/OCF N/A
P/B 3.21
P/tB 3.21
EV/EBITDA N/A
EPS(TTM)-2.17
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0.1
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.9%
ROE -141.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.21
Quick Ratio 11.21
Altman-Z -51.71
F-Score2
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)64.52%
Cap/Depr(5y)80.64%
Cap/Sales(3y)5.28%
Cap/Sales(5y)4.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.35%
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue 1Y (TTM)-96.76%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%
EBIT growth 1Y8.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.62%
OCF growth 3YN/A
OCF growth 5YN/A